Interest of acridine derivatives in the anticancer chemotherapy

被引:202
作者
Demeunynck, M [1 ]
Charmantray, F [1 ]
Martelli, A [1 ]
机构
[1] Univ Grenoble 1, UMR CNRS 5616, LEDSS, Chim Bioorgan Lab, F-38041 Grenoble 9, France
关键词
D O I
10.2174/1381612013397131
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
DNA is considered as one of the main targets for anticancer drug design. The planar structure of acridines confers to the molecules the ability to bind DNA by intercalation and therefore to interfere with metabolic processes. A large number of natural alkaloids and synthetic acridine derivatives have been tested as anticancer agents. So far, a few molecules have entered clinical trials and have been approved for chemotherapy. The mechanisms of action are not fully understood. Cytotoxicity may be related to potent enzyme inhibition. Topoisomerase and telomerase activities may be strongly affected by acridines. The affinity of acridines for DNA has also been used to design new active compounds in which a DNA modifying group is tethered to the acridine nucleus. Acridine derivatives display other pharmacological properties such as antibacterial and antimalarial activities. They are also tested for Alzheimer's disease.
引用
收藏
页码:1703 / 1724
页数:22
相关论文
共 103 条
[61]   Hypoxia-selective antitumor agents .13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide [J].
Lee, HH ;
Wilson, WR ;
Ferry, DM ;
vanZijl, P ;
Pullen, SM ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (13) :2508-2517
[62]  
Lee HH, 1999, ANTI-CANCER DRUG DES, V14, P487
[63]  
Lehne Gustav, 2000, Current Drug Targets, V1, P85, DOI 10.2174/1389450003349443
[64]  
LHOMME J, 1994, Patent No. 9425439
[65]   DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS [J].
LIU, LF .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :351-375
[66]  
Luedtke NW, 2000, ANGEW CHEM INT EDIT, V39, P1788, DOI 10.1002/(SICI)1521-3773(20000515)39:10<1788::AID-ANIE1788>3.0.CO
[67]  
2-6
[68]   Prospects for the therapeutic use of antigene oligonucleotides [J].
Maher, LJ .
CANCER INVESTIGATION, 1996, 14 (01) :66-82
[69]   Preclinical and clinical pharmacology of antisense oligonucleotides [J].
Marcusson, EG ;
Yacyshyn, BR ;
Shanahan, WR ;
Dean, NM .
MOLECULAR BIOTECHNOLOGY, 1999, 12 (01) :1-11
[70]  
MATSUMOTO SS, 1999, P AM ASSOC CANC RES, V40, pA1914